|
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
Number of employees : 473 people.
|
|
| 2020 | 2021 | Delta | Collaboration | 0.54 | 75.5% | 913.08 | 99.8% | +168054.88% |
Grant | 0.18 | 24.5% | 1.88 | 0.2% | +969.32% |
USD in Million |
|
|
| 2020 | 2021 | Delta | Switzerland and United States | 0.72 | 100% | 914.96 | 100% | +127154.94% |
USD in Million |
|
|
| Vote  | Quantity | Free-Float | Company-owned shares | Total Float |
Stock A |
1 |
78,474,455 |
77,228,142 |
98.4% |
180,316 |
0.2% |
98.4% |
|
|
Name | Equities | % | ARK Investment Management LLC | 7,829,932 |
10.0% | Capital Research & Management Co. (International Investors) | 5,342,418 |
6.82% | Nikko Asset Management Americas, Inc. | 4,262,736 |
5.44% | T. Rowe Price Investment Management, Inc. | 2,241,445 |
2.86% | NEA Management Co. LLC | 1,590,002 |
2.03% | SSgA Funds Management, Inc. | 1,568,384 |
2.00% | The Vanguard Group, Inc. | 1,350,107 |
1.72% | Perceptive Advisors LLC | 1,341,308 |
1.71% | Fidelity Management & Research Co. LLC | 1,317,981 |
1.68% | Loomis, Sayles & Co. LP | 1,245,199 |
1.59% |
|
Company contact information |
|
|
|
|
Sector Other Biotechnology & Medical Research
| | 1st jan. | Capi. (M$) |
 | CRISPR THERAPEUTICS AG | 29.84% | 4 132 |
| | | |
 | MODERNA, INC. | 5.42% | 72 745 |
 | LONZA GROUP AG | 17.24% | 42 787 |
 | IQVIA HOLDINGS INC. | 12.00% | 42 622 |
 | ALNYLAM PHARMACEUTICALS, INC. | -2.64% | 28 465 |
 | SEAGEN INC. | 9.46% | 26 117 |
 | CELLTRION, INC. | 3.93% | 19 410 |
 | ICON PUBLIC LIMITED COMPANY | 17.50% | 18 635 |
 | HANGZHOU TIGERMED CONSULTING CO., LTD. | 17.73% | 15 274 |
 | PHARMARON BEIJING CO., LTD. | 21.62% | 13 857 |
 | BIO-TECHNE CORPORATION | -2.04% | 12 744 |
 | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | 12.48% | 12 470 |
 | UNITED THERAPEUTICS CORPORATION | -6.62% | 11 835 |
 | QIAGEN N.V. | -1.14% | 11 226 |
 | GENSCRIPT BIOTECH CORPORATION | 18.11% | 7 929 |
 | MEDPACE HOLDINGS, INC. | 5.31% | 6 938 |
 | BACHEM HOLDING AG | 3.88% | 6 642 |
 | ROIVANT SCIENCES LTD. | 7.01% | 6 202 |
 | IONIS PHARMACEUTICALS, INC. | 5.96% | 5 685 |
 | PROMETHEUS BIOSCIENCES, INC. | 5.56% | 5 398 |
 | JOINN LABORATORIES(CHINA)CO.,LTD. | 13.73% | 4 913 |
Connections : CRISPR Therapeutics AG
|